Vtv Therapeutics Inc. current report, 25 June 2019

Vollständiges Dokument

Business Context and Reporting Period

This Form 8-K Current Report was filed by vTv Therapeutics Inc. on June 26, 2019, covering events occurring on June 25, 2019. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in High Point, NC. Its Class A common stock trades on the NASDAQ Capital Market under the symbol VTVT.

Key Financial Metrics

The filing reports a specific capital raise event rather than comprehensive financial statements. Key metrics disclosed include:

  • Capital Raised: $2.0 million.
  • Shares Issued: 1,212,121 shares of Class A common stock.
  • Price Per Share: $1.65.
  • Investor: MacAndrews & Forbes Group LLC.

The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions outside of this specific transaction.

Material Changes

The material change reported is the execution of a provision within the "March 2019 Letter Agreement." On June 25, 2019, the Company exercised its right to require the Investor to purchase the aforementioned shares. This transaction resulted in an immediate increase in the Company's cash position and an increase in outstanding shares.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction details are qualified by reference to the March 2019 Letter Agreement (Exhibit 10.2 of the March 20, 2019 Form 8-K). No unusual items or contingencies were disclosed in this specific report.

Investor Verification Checklist

  • Verify the terms of the March 2019 Letter Agreement referenced in the filing to understand the full scope of the investment relationship.
  • Confirm the post-transaction share count and dilution impact on existing shareholders.
  • Review the Company's most recent 10-Q or 10-K to assess overall liquidity and cash burn rates, as this 8-K only details a single funding event.
  • Check for any subsequent filings regarding the use of the $2.0 million proceeds.